
Release date: 2026-04-02 15:46:02 Article From: Lucius Laos Recommended: 15
In clinical studies, some common side effects were reported in patients taking belumosudil. These included infections, fatigue or weakness, nausea, diarrhea, shortness of breath, and cough. Some patients may also experience swelling, bleeding, abdominal pain, muscle or bone pain, headache, and high blood pressure. This is not a complete list of possible side effects. If you experience any discomfort, especially if the above symptoms become severe or persistent, consult your doctor promptly. Depending on the severity of your side effects, your doctor may adjust your dosage, suspend treatment, or in rare cases, discontinue treatment permanently.
Belumosudil may cause harm to an unborn baby, so strict contraceptive measures are essential during treatment. If you could become pregnant, your doctor will perform a pregnancy test before starting therapy. Women of childbearing potential must use effective contraception during treatment and for 1 week after the last dose. Similarly, men with female partners of childbearing potential should also use effective contraception during the same period. If you become pregnant or suspect you may be pregnant while taking this medication, inform your doctor immediately. In addition, as it is unknown whether belumosudil passes into breast milk, breastfeeding should be avoided during treatment and for 1 week after the last administration.
Belumosudil may affect fertility in both males and females. If you have concerns about this, a detailed discussion with your healthcare provider prior to treatment is recommended. To ensure safe use, your doctor will conduct necessary monitoring throughout your treatment. Importantly, your healthcare provider will perform blood tests at least monthly to monitor your liver function. Regular monitoring helps detect potential problems early and intervene, ensuring safe and continuous treatment. Be sure to follow all monitoring instructions from your doctor and report any physical changes proactively.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:2172025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4502024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:2242025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:2392025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:2172025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:2462025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2292025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2142025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: